Dr. Eva Schernhammer Photo

Eva Schernhammer, D.P.H., M.D.

Adjunct Professor of Epidemiology, Harvard T.H. Chan School of Public Health
Lecturer on Medicine, Part-time, Brigham and Women's Hospital
Harvard Titles

Adjunct Professor Epidemiology, Harvard T.H. Chan School of Public Health
Lecturer on Medicine, Part-time

Other Affiliations

Channing Division of Network Medicine, Brigham and Women's Hospital

Address

Channing Laboratory
181 Longwood Avenue, 4th Floor, Room 444
Boston, MA 02115

Publications View
Intra-individual dose escalation with carboplatin/mitomycin C in advanced breast cancer
Authors: Kienzer H, Baur M, Faezeny M, DeSantis M, Poehnl R, Schernhammer E, Postner G, Kraus R, Point J, Dittrich C
Ann Oncol (Pro ESMO, Athens, Greece)
Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine.
Authors: Czejka M, Bandak S, Simon D, Schüller J, Weiss C, Schernhammer E.
Z Naturforsch C J Biosci
View full abstract on Pubmed
[Drug interactions between interferon alpha 2b and 5-fluorouracil during continuous intravenous 5FU infusion].
Authors: Czejka M, Schüller J, Schernhammer E, Bandak S.
Pharmazie
View full abstract on Pubmed
Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells.
Authors: Bandak S, Czejka M, Schüller J, Schernhammer E.
Arzneimittelforschung
View full abstract on Pubmed
Dexverapamil to overcome epirubicin resistance in advanced breast cancer.
Authors: Thürlimann B, Kröger N, Greiner J, Mross K, Schüller J, Schernhammer E, Schumacher K, Gastl G, Hartlapp J, Kupper H, et al.
J Cancer Res Clin Oncol
View full abstract on Pubmed
Pharmacokinetic interaction between 4’-epidoxorubicin and the multidrug resistance reverting agent quinine
Authors: Czejka M, Bandak S, Simon D, Schueller J, Weiss C, Schernhammer E
Z Naturforschung
Epirubicin pharmacokinetics, influence of interferon alfa 2b in advanced cancer patients
Authors: Schueller J, Czejka M, Bandak S, Wirth M, Schernhammer E, Schernthaner G
Pro ASCO, Dallas, TX
Light and Dark Activity and Rest in Dayshift and Nightshift Nurses
Authors: Rea M, Biermann A, Figueiro M, Zhou Y, Schernhammer E
Pro Society for Light Treatment and Biological Rhythms (SLTBR) 19th Annual Meeting, Copenhagen, Denmark, 2007
Therapie von Karzinomschmerzen
Authors: Schueller J, Schernhammer E, Weiss C, Fogl U
3
IARC monographs on the evaluation of carcinogenic risks to humans
Authors: IARC, Monograph Working Group [Member]
Volume 98